Evidence map›Paper›PMID 35885068›Full record

ArticleBiomedicines2022

The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane.

Erik Őrfi, László Hricisák, László Dézsi, Péter Hamar, Zoltán Benyó, János Szebeni, Gábor Szénási

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Erik ŐrfiInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-2190-0708
László HricisákInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
László DézsiInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Péter HamarInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-1095-3564
Zoltán BenyóInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0001-6015-0359
János SzebeniInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.
Gábor SzénásiInstitute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-7350-6091
Semmelweis University · HU

Funding

European Commission Horizon 2020 825828 "Expert"European Commission Horizon 2020 952520 "Biosafety"Hungarian Scientific Research Fund K-101775Hungarian Scientific Research Fund K-113164Hungarian Scientific Research Fund K-115623Hungarian Scientific Research Fund K-125174Ministry for Innovation and Technology ÚNKP-19-3-IIINational Research, Development and Innovation Office 2020-1.1.6-JÖVŐ-2021-00013University of Miskolc Applied Materials and Nanotechnology Center of Excellence
6 · The paper itself

Abstract

Liposomal amphotericin B (Abelcet) can cause infusion (anaphylactoid) reactions in patients whose mechanism is poorly understood. Here, we used mice to investigate the role of complement (C) receptors and the cellular sources of vasoactive mediators in these reactions. Anesthetized male NMRI and thromboxane prostanoid receptor (TP) or cyclooxygenase-1 (COX-1)-deficient and wild type C57Bl6/N mice were intravenously injected with Abelcet at 30 mg/kg. Mean arterial blood pressure (MABP) and heart rate (HR) were measured. In untreated mice, Abelcet caused a short (15 min) but large (30%) increase in MABP. C depletion with cobra venom factor (CVF) and inhibition of C5a receptors with DF2593A considerably prolonged, while C3aR inhibition with SB290157 significantly decreased the hypertensive effect. Likewise, the hypertensive response was abolished in COX-1- and TP-deficient mice. CVF caused a late hypertension in TP-deficient mice. Both macrophage depletion with liposomal clodronate and blockade of platelet GPIIb/IIIa receptors with eptifibatide prolonged the hypertensive effect. The early phase of the hypertensive effect is COX-1- and TP-receptor-dependent, partly mediated by C3aR. In contrast, the late phase is under the control of vasoactive mediators released from platelets and macrophages subsequent to complement activation and C5a binding to its receptor.

Indexed as

cobra venom factorgranulocytesinfusion reactionplatelets

Identifiers

PMID35885068
PMCPMC9313435
OpenAlexW4286111450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.